Related Experiment Videos
Dynamics of coronary thrombolysis and reocclusion
1Cardiovascular Thrombosis Research Center, Division of Cardiovascular Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts 01655-0214, USA.
Insights
Coronary thrombosis involves complex atherosclerotic plaque development. While thrombolytic therapy dissolves clots, it can increase reocclusion risk, making thrombin and platelet inhibition key research areas.
Area of Science:
- Cardiovascular Biology
- Thrombosis Research
- Vascular Medicine
Background:
- Coronary thrombosis pathobiology is complex and not fully understood.
- Atherosclerotic plaque development initiates the process, involving endothelial dysfunction and altered vascular thromboresistance.
- Plaque disruption leads to platelet aggregation and fibrin formation.
Purpose of the Study:
- To elucidate the complex dynamics of coronary thrombosis and reocclusion.
- To highlight the role of thrombin and platelets in the reocclusion process after thrombolytic therapy.
- To review current and emerging therapeutic strategies targeting thrombin and platelets.
Main Methods:
- Review of the pathobiology of coronary thrombosis.
- Analysis of the mechanisms of reocclusion following thrombolytic therapy.
- Investigation of therapeutic targets including thrombin and platelets.
Main Results:
- Thrombolytic therapy, while effective, generates a procoagulant state.
- Plasmin generated during thrombolysis activates platelets and thrombin, increasing reocclusion likelihood.
- Thrombin and activated platelets are critical in the reocclusion cascade.
Conclusions:
- Thrombin is a significant target for therapeutic intervention in coronary thrombosis.
- Novel thrombin inhibitors are under development.
- Potent antiplatelet agents are being investigated to prevent reocclusion after thrombolytic therapy.
Abstract:
The dynamics of coronary thrombosis and reocclusion may seem straightforward, but in actuality they are complex and incompletely understood. The pathobiology of coronary thrombosis begins with the development of the atherosclerotic plaque. The initial step in the process, endothelial cell dysfunction, alters vascular thromboresistance. Plaque erosion or overt disruption is followed by platelet adherence, aggregation, and thrombin generation that stimulates the conversion of soluble fibrinogen to fibrin. Thrombolytic therapy, although able to dissolve a high proportion of occlusive thrombi, creates a procoagulant environment by generating plasmin which, in turn, activates platelets and generates thrombin, increasing the likelihood of vessel reocclusion. Thrombin is therefore considered an important target for research, and several thrombin inhibitors have been developed. Antiplatelet agents such as aspirin are currently employed to prevent reocclusion following thrombolytic therapy; however, several new and more potent platelet antagonists are being investigated with considerable enthusiasm.